

## **ANNEX: Actual SmPC for Hemilibra**

### **Summary of Product Characteristics for Pharmaceutical Products**

#### **1. Name of the medicinal product**

Hemlibra 30 mg/1 mL solution for injection  
Hemlibra 60 mg/0.4 mL solution for injection  
Hemlibra 105 mg/0.7 mL solution for injection  
Hemlibra 150 mg/1 mL solution for injection

#### **2. Qualitative and quantitative composition**

Hemlibra 30 mg/1 mL solution for injection  
Each vial of 1 mL contains 30 mg of emicizumab at a concentration of 30 mg/mL.

Hemlibra 60 mg/0.4 mL solution for injection  
Each vial of 0.4 mL contains 60 mg of emicizumab at a concentration of 150 mg/mL.

Hemlibra 105 mg/0.7 mL solution for injection  
Each vial of 0.7 mL contains 105 mg of emicizumab at a concentration of 150 mg/mL.

Hemlibra 150 mg/1 mL solution for injection  
Each vial of 1 mL contains 150 mg of emicizumab at a concentration of 150 mg/mL.

Emicizumab is a humanised monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure bridging factor IXa and factor X produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.

For the full list of excipients, see section 6.1. For the full list of excipients, see section 6.1

#### **3. Pharmaceutical form**

Solution for injection.

Colourless to slightly yellow solution.

#### **4. Clinical particulars**

##### **4.1 Therapeutic indications**

Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):

##### **4.2 Posology and method of administration**

Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia and/or bleeding disorders.

#### Posology

Treatment (including routine prophylaxis) with bypassing agents (e.g. activated prothrombin complex concentrate [aPCC] and activated recombinant human FVII [rFVIIa]) should be discontinued the day before starting Hemlibra therapy (see section 4.4).

Factor VIII (FVIII) prophylaxis may be continued for the first 7 days of Hemlibra treatment.

The recommended dose is 3 mg/kg once weekly for the first 4 weeks (loading dose), followed by a maintenance dose from week 5, of either 1.5 mg/kg once weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks, all doses administered as a subcutaneous injection.

The loading dose regimen is the same, irrespective of the maintenance dose regimen.

The maintenance dose regimen should be selected based on physician and patient/caregiver dosing regimen preference to support adherence.

The patient dose (in mg) and volume (in mL) should be calculated as follows:

- Loading dose (3 mg/kg) once weekly for the first 4 weeks:

Patient bodyweight (kg) x dose (3 mg/kg) = total amount (mg) of emicizumab to be administered

- Followed by a maintenance dose from week 5, of either 1.5 mg/kg once weekly, 3 mg/kg every two weeks or 6 mg/kg every four weeks:

Patient bodyweight (kg) x dose (1.5; 3 or 6 mg/kg) = total amount (mg) of emicizumab to be administered  
The total volume of Hemlibra to be injected subcutaneously is calculated as follows:

Total amount (mg) of emicizumab to be administered ÷ vial concentration (mg/mL) = total volume of Hemlibra (mL) to be injected.

Different Hemlibra concentrations (30 mg/mL and 150 mg/mL) should not be combined in the same syringe when making up the total volume to be administered.

A volume greater than 2 mL per injection should not be administered. Examples:

Patient's bodyweight of 16 kg, under a maintenance dose regimen of 1.5 mg/kg once weekly:

- Loading dose (first 4 weeks) example: 16 kg x 3 mg/kg = 48 mg of emicizumab needed for the loading dose.
- To calculate the volume to be administered divide calculated dose 48

mg by 150 mg/mL:  $48 \text{ mg of emicizumab} \div 150 \text{ mg/mL} = 0.32 \text{ mL}$  of 150 mg/mL Hemlibra concentration to be injected.

- Choose appropriate dose and volume from vial strengths available.
- Maintenance dose (from week 5 on) example:  $16 \text{ kg} \times 1.5 \text{ mg/kg} = 24 \text{ mg}$  of emicizumab needed for the maintenance dose.
- To calculate the volume to be administered divide calculated dose 24 mg by 30 mg/mL:  $24 \text{ mg of emicizumab} \div 30 \text{ mg/mL} = 0.8 \text{ mL}$  of 30 mg/mL Hemlibra concentration to be injected once weekly.
- Choose appropriate dose and volume from vial strength available.

Patient's bodyweight of 40 kg, under a maintenance dose regimen of 3 mg/kg every two weeks:

- Loading dose (first 4 weeks) example:  $40 \text{ kg} \times 3 \text{ mg/kg} = 120 \text{ mg}$  of emicizumab needed for the loading dose.
- To calculate the volume to be administered divide calculated dose 120 mg by 150 mg/mL:  $120 \text{ mg of emicizumab} \div 150 \text{ mg/mL} = 0.8 \text{ mL}$  of 150 mg/mL Hemlibra concentration to be injected.
- Choose appropriate dose and volume from vial strengths available.
- Maintenance dose (from week 5 on) example:  $40 \text{ kg} \times 3 \text{ mg/kg} = 120 \text{ mg}$  of emicizumab needed for the maintenance dose.
- To calculate the volume to be administered divide calculated dose 120 mg by 150 mg/mL:  $120 \text{ mg of emicizumab} \div 150 \text{ mg/mL} = 0.8 \text{ mL}$  of 150 mg/mL Hemlibra concentration to be injected every two weeks.
- Choose appropriate dose and volume from vial strength available.

Patient's bodyweight of 60 kg, under a maintenance dose regimen of 6 mg/kg every four weeks:

- Loading dose (first 4 weeks) example:  $60 \text{ kg} \times 3 \text{ mg/kg} = 180 \text{ mg}$  of emicizumab needed for the loading dose.
- To calculate the volume to be administered divide calculated dose 180 mg by 150 mg/mL:  $180 \text{ mg of emicizumab} \div 150 \text{ mg/mL} = 1.20 \text{ mL}$  of 150 mg/mL Hemlibra concentration to be injected.
- Choose appropriate dose and volume from vial strengths available.
- Maintenance dose (from week 5 on) example:  $60 \text{ kg} \times 6 \text{ mg/kg} = 360 \text{ mg}$  of emicizumab needed for the maintenance dose.
- To calculate the volume to be administered divide calculated dose 360 mg by 150 mg/mL:  $360 \text{ mg of emicizumab} \div 150 \text{ mg/mL} = 2.4 \text{ mL}$  of 150 mg/mL Hemlibra concentration to be injected every four weeks.
- Choose appropriate dose and volume from vial strengths available.

### Duration of treatment

Hemlibra is intended for long-term prophylactic treatment.

### Dose adjustments during treatment

No dose adjustments of Hemlibra are recommended.

### Delayed or missed doses

If a patient misses a scheduled subcutaneous injection of Hemlibra, the patient should be instructed to take the missed dose as soon as possible, up to a day before the day of the next scheduled dose. The patient should then administer the next dose on the usual scheduled dosing day. The patient should not take two doses on the same day to make up for a missed dose.

### Special populations

#### Paediatric

No dose adjustments are recommended in paediatric patients (see section 5.2). There are no data in patients less than 1 year of age.

#### Elderly

No dose adjustments are recommended in patients  $\geq 65$  years of age (see sections 5.1 and 5.2). There are no data in patients over 77 years old.

#### Renal and hepatic impairment

No dose adjustments are recommended in patients with mild, renal or hepatic impairment (see section 5.2). There are limited data available on the use of Hemlibra in patients with moderate renal or hepatic impairment. Emicizumab has not been studied in patients with severe renal or hepatic impairment

#### Management in the perioperative setting

The safety and efficacy of emicizumab have not been formally evaluated in the surgical setting. Patients have had surgical procedures without discontinuing emicizumab prophylaxis in clinical studies.

If bypassing agents (e.g. aPCC and rFVIIa) are required in the perioperative period, please refer to the dosing guidance on the use of bypassing agents in section 4.4. If FVIII is required in the perioperative period, please refer to section 4.5.

When monitoring a patient's underlying haemostatic activity, please refer to section 4.4 for laboratory tests unaffected by emicizumab.

#### Immune tolerance induction (ITI)

The safety and efficacy of emicizumab in patients receiving ongoing immune tolerance induction have not yet been established. No data are available.

### Method of administration

Hemlibra is for subcutaneous use only, and it should be administered using appropriate aseptic technique (see section 6.6).

The injection should be restricted to the recommended injection sites: the abdomen, the upper outer arms and the thighs (see section 5.2).

Administration of Hemlibra subcutaneous injection in the upper outer arm should be performed by a caregiver or healthcare professional.

Alternating the site of injection may help prevent or reduce injection site reactions (see section 4.8). Hemlibra subcutaneous injection should not be administered into areas where the skin is red, bruised, tender or hard, or areas where there are moles or scars.

During treatment with Hemlibra, other medicinal products for subcutaneous administration should, preferably, be injected at different anatomical sites.

### Administration by the patient and/or caregiver

Hemlibra is intended for use under the guidance of a healthcare professional. After proper training in subcutaneous injection technique, a patient may self-inject Hemlibra, or the patient's caregiver may administer it, if their physician determines that it is appropriate.

The physician and the caregiver should determine the appropriateness of the child self-injecting Hemlibra. However, self-administration is not recommended for children below 7 years of age.

For comprehensive instructions on the administration of Hemlibra, see section 6.6 and package leaflet.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

### Thrombotic microangiopathy associated with Hemlibra and aPCC

Cases of thrombotic microangiopathy (TMA) were reported from a clinical study in patients receiving Hemlibra prophylaxis when on average a cumulative amount of >100U/kg/24 hours of aPCC for 24 hours or more was administered (see section 4.8). Treatment for the TMA events included supportive care with or without plasmapheresis

and haemodialysis. Evidence of improvement was seen within one week following discontinuation of aPCC and interruption of Hemlibra. This rapid improvement is distinct from the usual clinical course observed in atypical hemolytic uremic syndrome and classic TMAs, such as thrombotic thrombocytopenic purpura (see section 4.8). One patient resumed Hemlibra following resolution of TMA and continued to be treated safely.

Patients receiving Hemlibra prophylaxis should be monitored for the development of TMA when administering aPCC. The physician should immediately discontinue aPCC and interrupt Hemlibra therapy if clinical symptoms and/or laboratory findings consistent with TMA occur, and manage as clinically indicated. Physicians and patients/caregivers should weigh the benefits and risks of resuming Hemlibra prophylaxis following complete resolution of TMA on a case-by-case basis. In case a bypassing agent is indicated in a patient receiving Hemlibra prophylaxis, see below for dosing guidance on the use of bypassing agents.

Caution should be used when treating patients who are at high risk for TMA (e.g. have a previous medical history or family history of TMA), or those who are receiving concomitant medicinal products known to be a risk factor for the development of TMA (e.g. ciclosporin, quinine, tacrolimus).

#### Thromboembolism associated with Hemlibra and aPCC

Serious thrombotic events were reported from a clinical study in patients receiving Hemlibra prophylaxis when on average a cumulative amount of >100U/kg/24 hours of aPCC for 24 hours or more was administered (see section 4.8). No cases required anticoagulation therapy. Following discontinuation of aPCC and interruption of Hemlibra, evidence of improvement or resolution was seen within one month (see section 4.8). One patient resumed Hemlibra following resolution of thrombotic event and continued to be treated safely.

Patients receiving Hemlibra prophylaxis should be monitored for the development of thromboembolism when administering aPCC. The physician should immediately discontinue aPCC and interrupt Hemlibra therapy if clinical symptoms, imaging, and/or laboratory findings consistent with thrombotic events occur, and manage as clinically indicated. Physicians and patients/caregivers should weigh the benefits and risks of resuming Hemlibra prophylaxis following complete resolution of thrombotic events on a case-by-case basis. In case a bypassing agent is indicated in a patient receiving Hemlibra prophylaxis, see below for dosing guidance on the use of bypassing agents.

#### Guidance on the use of bypassing agents in patients receiving Hemlibra prophylaxis

Treatment with bypassing agents should be discontinued the day before

starting Hemlibra therapy.

Physicians should discuss with all patients and/or caregivers the exact dose and schedule of bypassing agents to use, if required while receiving Hemlibra prophylaxis.

Hemlibra increases the patient's coagulation potential. The bypassing agent dose required may therefore be lower than that used without Hemlibra prophylaxis. The dose and duration of treatment with bypassing agents will depend on the location and extent of bleeding, and the patient's clinical condition. Use of aPCC should be avoided unless no other treatment options/alternatives are available. If aPCC is indicated in a patient receiving Hemlibra prophylaxis, the initial dose should not exceed 50 U/kg and laboratory monitoring is recommended (including but not restricted to renal monitoring, platelet testing, and evaluation of thrombosis). If bleeding is not controlled with the initial dose of aPCC up to 50 U/kg, additional aPCC doses should be administered under medical guidance or supervision with consideration made to laboratory monitoring for the diagnosis of TMA or thromboembolism and verification of bleeds prior to repeated dosing. The total aPCC dose should not exceed 100 U/kg in the first 24-hours of treatment. Treating physicians must carefully weigh the risk of TMA and thromboembolism against the risk of bleeding when considering aPCC treatment beyond a maximum of 100 U/kg in the first 24-hours.

In clinical studies, no cases of TMA or thrombotic events were observed with use of rFVIIa alone in patients receiving Hemlibra prophylaxis.

Bypassing agent dosing guidance should be followed for at least 6 months following discontinuation of Hemlibra prophylaxis (see section 5.2).

### Immunogenicity

Development of neutralising anti-emicizumab antibodies with decreasing emicizumab concentration leading to loss of efficacy has been uncommonly observed during clinical studies (see sections 4.8 and 5.1). Patients with clinical signs of loss of efficacy (e.g. increase in breakthrough bleeding events), should be promptly evaluated to assess the etiology and other therapeutic options should be considered if neutralising anti-emicizumab antibodies are suspected.

### Effects of emicizumab on coagulation tests

Emicizumab restores the tenase cofactor activity of missing activated factor VIII (FVIIIa). Coagulation laboratory tests based on intrinsic clotting, including the activated clotting time (ACT), activated partial thromboplastin time (e.g. aPTT), measure the total clotting time including time needed for activation of FVIII to FVIIIa by thrombin. Such intrinsic pathway based tests will yield overly shortened clotting times with emicizumab, which does not require activation by thrombin. The overly shortened intrinsic clotting time will then disturb all single

factor assays based on aPTT, such as the one stage FVIII activity assay (see section 4.4, Table 1). However, single factor assays utilising chromogenic or immuno- based methods are not affected by emicizumab and may be used to monitor coagulation parameters during treatment, with specific considerations for FVIII chromogenic activity assays as described below.

Chromogenic FVIII activity tests may be manufactured with either human or bovine coagulation proteins. Assays containing human coagulation factors are responsive to emicizumab but may overestimate the clinical haemostatic potential of emicizumab. In contrast, assays containing bovine coagulation factors are insensitive to emicizumab (no activity measured) and can be used to monitor endogenous or infused FVIII activity, or to measure anti FVIII inhibitors.

Emicizumab remains active in the presence of inhibitors against FVIII and so will produce a false negative result in

clotting based Bethesda assays for functional inhibition of FVIII. Instead, a chromogenic Bethesda assay utilising a bovine based FVIII chromogenic test that is insensitive to emicizumab may be used.

These two pharmacodynamic markers do not reflect the true haemostatic effect of emicizumab *in vivo* (aPTT is overly shortened and reported FVIII activity may be overestimated) but provide a relative indication of the pro-coagulant effect of emicizumab.

In summary, intrinsic pathway clotting-based laboratory test results in patients treated with Hemlibra should not be used to monitor its activity, determine dosing for factor replacement or anti-coagulation, or measure FVIII inhibitors titers.

Caution should be taken if intrinsic pathway clotting based laboratory tests are used, as misinterpretation of their results may lead to under-treatment of patients experiencing bleeding episodes, which can potentially result in severe or life- threatening bleeds.

Laboratory tests affected and unaffected by emicizumab are shown in Table 1 below. Due to its long half-life, these effects on coagulation assays may persist for up to 6 months after the last dose (see section 5.2).

**Table 1 Coagulation test results affected and unaffected by emicizumab**

Results affected by emicizumab	Results unaffected by emicizumab
--------------------------------	----------------------------------



- Activated partial thromboplastin time (aPTT)	- Bethesda assays (bovine chromogenic) for FVIII inhibitor titers
- Bethesda assays (clotting-based) for FVIII inhibitor titers	- Thrombin time (TT)
- One-stage, aPTT-based, single-factor assays	- One-stage, prothrombin time (PT)-based, single-factor assays
- aPTT-based activated protein C resistance (APC-R)	- Chromogenic-based single-factor assays other than FVIII <sup>1</sup>
- Activated clotting time (ACT)	- Immuno-based assays (e.g. ELISA, turbidimetric methods)
	- Genetic tests of coagulation factors (e.g. Factor V Leiden, Prothrombin 20210)

<sup>1</sup>For important considerations regarding FVIII chromogenic activity assays, see section 4.4.

#### Paediatric population

There are no data in children < 1 year of age. The developing haemostatic system in neonates and infants is dynamic and evolving, and the relative concentrations of pro- and anticoagulant proteins in these patients should be taken into consideration when making a benefit-risk assessment, including potential risk of thrombosis (e.g. central venous catheter-related thrombosis).

#### **4.5 Interaction with other medicinal products and other forms of interaction**

No adequate or well-controlled interaction studies have been conducted with emicizumab.

Clinical experience indicates a medicinal product interaction exists with emicizumab and aPCC (see sections 4.4 and 4.8).

There is a possibility for hypercoagulability with rFVIIa or FVIII with emicizumab based on preclinical experiments. Emicizumab increases coagulation potential, therefore the FVIIa or FVIII dose required to achieve haemostasis may be lower than when used without Hemlibra prophylaxis.

In case of thrombotic complication, the physician should consider discontinuing rFVIIa or FVIII and interrupt Hemlibra prophylaxis as clinically indicated. Further management should be tailored to the individual clinical circumstances.

- Decision about dose modifications should take into account the half-life of medicinal products; specifically, interruption of emicizumab may not have an immediate effect.
- Monitoring using a FVIII chromogenic assay may guide the administration of coagulation factors, and testing for thrombophilic traits may be considered.

Experience with concomitant administration of anti-fibrinolytics with aPCC or rFVIIa in patients receiving Hemlibra prophylaxis is limited. However, the possibility of thrombotic events should be considered when systemic anti-fibrinolytics are used in combination with aPCC or rFVIIa in patients receiving emicizumab.

#### **4.6 Fertility, pregnancy and lactation**

##### Women of childbearing potential/Contraception

Women of childbearing potential receiving Hemlibra should use effective contraception during, and for at least 6 months after cessation of Hemlibra treatment (see section 5.2).

##### Pregnancy

There are no clinical studies of emicizumab use in pregnant women. Animal reproduction studies have not been conducted with Hemlibra. It is not known whether emicizumab can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Hemlibra should be used during pregnancy only if the potential benefit for the mother outweighs the potential risk to the fetus taking into account that, during pregnancy and after parturition, the risk for thrombosis is increased and that several pregnancy complications are linked to an increased risk for disseminated intravascular coagulation (DIC).

##### Breast-feeding

It is not known whether emicizumab is excreted in human milk. No studies have been conducted to assess the impact of emicizumab on milk production or its presence in breast milk. Human IgG is known to be present in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Hemlibra therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

##### Fertility

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). No fertility data are available in humans. Thus, the effect of emicizumab on male and female fertility is unknown.

#### **4.7 Effects on ability to drive and use machines**

Hemlibra has no or negligible influence on the ability to drive and use machines.

#### **4.8 Undesirable effects**

##### Summary of the safety profile

The overall safety profile of Hemlibra is based on data from clinical

studies and post-marketing surveillance. The most serious adverse drug reactions (ADRs) reported from the clinical studies with Hemlibra were thrombotic microangiopathy (TMA) and thrombotic events, including cavernous sinus thrombosis (CST) and superficial vein thrombosis contemporaneous with skin necrosis (see below and section 4.4).

The most common ADRs reported in  $\geq 10\%$  of patients treated with at least one dose of Hemlibra were: injection site reactions (19.4 %), arthralgia (14.2 %) and headache (14.0 %).

In total three patients (0.7 %) in the clinical studies receiving Hemlibra prophylaxis withdrew from treatment due to ADRs, which were TMA, skin necrosis contemporaneous with superficial thrombophlebitis, and headache.

#### Tabulated list of adverse drug reactions

The following adverse drug reactions (ADRs) are based on data from post-marketing surveillance and pooled data from five phase III clinical studies (adult and adolescent studies [BH29884 - HAVEN 1, BH30071 - HAVEN 3, and BO39182 - HAVEN 4], an all-age group study [BO41423 - HAVEN 6], and a paediatric study [BH29992 - HAVEN 2]), in which a total of 444 patients with haemophilia A received at least one dose of Hemlibra as routine prophylaxis (see section 5.1). Three hundred and seven (69.1 %) of the clinical study participants were adults (of which two were female), 61 (13.7 %) were adolescents ( $\geq 12$  to  $< 18$  years), 71 (16.0 %) were children ( $\geq 2$  to  $< 12$  years) and five (1.1 %) were infants and toddlers (1 month to  $< 2$  years). The median duration of exposure across the studies was 32 weeks (range: 0.1 to 94.3 weeks).

ADRs from the phase III clinical studies and post-marketing surveillance are listed by MedDRA system organ class (Table 2). The corresponding frequency categories for each ADR are based on the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ), very rare ( $< 1/10,000$ ) and not known (cannot be estimated from the available data).

**Table 2 Summary of adverse drug reactions from pooled HAVEN clinical studies and post-marketing surveillance with Hemlibra**

<b>System Organ Class (SOC)</b>	<b>Adverse reactions</b> (preferred term, MedDRA)	<b>Frequency</b>
Blood and lymphatic system disorders	Thrombotic microangiopathy	Uncommon
Nervous system disorders	Headache	Very common
Vascular disorders	Thrombophlebitis superficial	Uncommon
	Cavernous sinus thrombosis <sup>a</sup>	Uncommon
Gastrointestinal disorders	Diarrhoea	Common
Skin and subcutaneous tissue disorders	Skin necrosis	Uncommon
	Angioedema	Uncommon
	Urticaria	Common
	Rash	Common
Musculoskeletal and connective tissue disorders	Arthralgia	Very common
	Myalgia	Common
General disorders and administration site conditions	Injection site reaction	Very common
	Pyrexia	Common
	Therapeutic response decreased <sup>b</sup>	Uncommon

<sup>a</sup>Vascular disorders is a secondary SOC for cavernous sinus thrombosis.

<sup>b</sup>Loss of efficacy (therapeutic response decreased) manifest as an increase in breakthrough bleeding has been reported with neutralising anti-emicizumab antibodies with decreasing emicizumab concentration (see Description of selected adverse drug reactions and sections 4.4 and 5.1).

## Description of selected adverse drug reactions

### Thrombotic microangiopathy

In pooled phase III clinical studies, (TMA) events were reported in less than 1 % of patients (3/444) and in 9.7 % of patients (3/31) who received at least one dose of aPCC while being treated with emicizumab. All 3 TMAs occurred when on average a cumulative amount of > 100 U/Kg/24 hours of aPCC for 24 hours or more was administered during a treatment event (see section 4.4). Patients presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13 activity. One patient resumed Hemlibra following resolution of TMA without recurrence.

### Thrombotic events

In pooled phase III clinical studies, serious thrombotic events were reported in less than 1 % of patients (2/444) and in 6.5 % of patients (2/31) who received at least one dose of aPCC while being treated with emicizumab. Both serious thrombotic events occurred when on average a cumulative amount of > 100 U/Kg/24 hours of aPCC for 24 hours or more was administered during a treatment event. One patient resumed Hemlibra following resolution of the thrombotic event without recurrence (see section 4.4).

### Characterization of the interaction between emicizumab and aPCC treatment in pivotal clinical studies

There were 82 instances of aPCC treatment\* in patients receiving Hemlibra prophylaxis, of which eight instances (10%) consisted of on average a cumulative amount of >100 U/kg/24 hours of aPCC for 24 hours or more; two of the eight instances were associated with thrombotic events and three of the eight instances were associated with TMA (Table 3). No TMA or thrombotic events were associated with the remaining instances of aPCC treatment. Of all instances of aPCC treatment, 68 % consisted of only one infusion < 100 U/kg.

**Table 3 Characterisation of aPCC treatment\* in the pooled phase III clinical studies**

Duration of aPCC treatment	Average cumulative amount of aPCC over 24 hours (U/kg/24 hours)		
	<50	50–100	>100
<24 hours	9	47	13
24-48 hours	0	3	1 <sup>b</sup>
>48 hours	1	1	7 <sup>a,a,a,b</sup>

\* An instance of aPCC treatment is defined as all doses of aPCC received by a patient, for any reason, until there was a 36-hour treatment-free break. Includes all instances of aPCC treatment excluding those in the first 7 days and those that occurred 30 days after the discontinuation of Hemlibra.

<sup>a</sup> Thrombotic microangiopathy

<sup>b</sup> Thrombotic event

#### Injection site reactions

Injection site reactions (ISRs) were reported very commonly (19.4 %) from the pooled phase III clinical studies. All ISRs observed in the Hemlibra clinical studies were reported as being non-serious and mild to moderate in intensity, and 94.9

% resolved without treatment. The most commonly reported ISR symptoms were injection site erythema (10.6 %), injection site pain (4.1 %), injection site pruritus (2.9 %) and injection site swelling (2.7 %).

#### Immunogenicity

In the pooled phase III clinical studies with Hemlibra, development of neutralising anti-emicizumab antibodies associated with decreasing emicizumab concentration was uncommon (see section 5.1). One patient, who developed neutralising anti-emicizumab antibodies with decreasing emicizumab concentration, experienced loss of efficacy (manifest as breakthrough bleeding) after five weeks of treatment and later discontinued Hemlibra treatment (see sections 4.4 and 5.1).

#### Paediatric population

The paediatric population studied comprises a total of 137 patients, of which 5 (3.6 %) were infants and toddlers (1 month to less than 2 years of age), 71 (51.8 %) were children (from 2 to less than 12 years of age) and 61 (44.5 %) were adolescents (from 12 to less than 18 years old). The safety profile of Hemlibra was overall consistent between infants, children, adolescents, and adults.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below).

#### **Kenya**

Website: <https://pv.pharmacyboardkenya.org>

## **4.9 Overdose**

There is limited experience with overdose of Hemlibra.

## Symptoms

Accidental overdose may result in hypercoagulability.

## Management

Patients who receive an accidental overdose should immediately contact their physician and be monitored closely.

## **5. Pharmacological properties**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihemorrhagics, other systemic hemostatics;  
ATC code: B02BX06

#### Mechanism of action

Emicizumab is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure.

Emicizumab bridges activated factor IX and factor X to restore the function of missing FVIIIa that is needed for effective haemostasis.

Emicizumab has no structural relationship or sequence homology to FVIII and, as such, does not induce or enhance the development of direct inhibitors to FVIII.

#### Pharmacodynamics

Prophylactic therapy with Hemlibra shortens the aPTT and increases the reported FVIII activity (using a chromogenic assay with human coagulation factors). These two pharmacodynamic markers do not reflect the true haemostatic effect of emicizumab *in vivo* (aPTT is overly shortened and reported FVIII activity may be overestimated) but provide a relative indication of the pro-coagulant effect of emicizumab.

#### Clinical efficacy and safety

The efficacy of Hemlibra for routine prophylaxis in patients with haemophilia A was evaluated in five clinical studies (three adult and adolescent studies in patients with haemophilia A with or without FVIII inhibitors [HAVEN 1, HAVEN 3, and HAVEN 4], a paediatric study in patients with haemophilia A with FVIII inhibitors [HAVEN 2] and an all-age group study in patients with mild or moderate haemophilia A without FVIII inhibitors [HAVEN 6]).

#### Clinical studies in adult and adolescent patients with haemophilia A with or without FVIII inhibitors

*Patients (aged  $\geq 12$  years old and  $> 40$  kg) with haemophilia A without*

### *FVIII inhibitors (Study BH30071 – HAVEN 3)*

The HAVEN 3 study was a randomised, multicentre, open-label, phase III clinical study in 152 adult and adolescent males (aged  $\geq 12$  years and  $> 40$  kg) with severe haemophilia A without FVIII inhibitors who previously received either episodic (“on demand”) or prophylactic treatment with FVIII. Patients received subcutaneous Hemlibra, 3 mg/kg once weekly for the first four weeks followed by either 1.5 mg/kg once weekly (Arms A and D) or 3 mg/kg every two weeks (Arm B) thereafter, or no prophylaxis (Arm C). Patients in Arm C could switch to Hemlibra (3 mg/kg every two weeks) after completing at least 24 weeks without prophylaxis. For Arms A and B dose up-titration to 3 mg/kg weekly was allowed after 24 weeks for patients who experienced two or more qualified bleeds (i.e., spontaneous and clinically significant bleeds occurring at steady state). Arm D patients could up-titrate after the second qualifying bleed. At the time of the primary analysis, five patients underwent up-titration of their maintenance dose.

Eighty-nine patients previously treated with episodic (“on demand”) FVIII were randomized in a 2:2:1 ratio to receive Hemlibra either once weekly (Arm A; N = 36), every two weeks (Arm B; N = 35) or no prophylaxis (Arm C; N = 18), with stratification by prior 24-week bleed rate ( $< 9$  or  $\geq 9$ ). Sixty-three patients previously treated with prophylactic FVIII were enrolled into Arm D to receive Hemlibra (1.5 mg/kg once weekly).

The primary objective of the study was to evaluate in patients previously treated with episodic FVIII the efficacy of prophylactic Hemlibra weekly (Arm A) or every two weeks (Arm B) compared to no prophylaxis (Arm C) based on the number of bleeds requiring treatment with coagulation factors (see Table 4). Other objectives of the study included evaluation of the randomised comparison of Arms A or B and Arm C for the efficacy of Hemlibra prophylaxis in reducing the number of all bleeds, spontaneous bleeds, joint bleeds, and target joint bleeds (see Table 4), as well as assessing patient treatment preference using a preference survey.

The efficacy of Hemlibra prophylaxis was also compared with previous prophylactic FVIII treatment (Arm D) in patients who had participated in a non-interventional study (NIS) prior to enrollment (see Table 5). Only patients from the NIS were included in this comparison, because bleed and treatment data were collected with the same level of granularity as used in HAVEN 3. The NIS is an observational study with the main objective of capturing detailed clinical data on the bleeding episodes and haemophilia medicinal product use of patients with haemophilia A outside of an interventional study setting.

### *Patients (aged $\geq 12$ years old) with haemophilia A with FVIII inhibitors (Study BH29884 – HAVEN 1)*

The HAVEN 1 study was a randomised, multicentre, open-label clinical study in 109 adolescent and adult males (aged  $\geq 12$  years old) with



haemophilia A with FVIII inhibitors who had previously received either episodic or prophylactic treatment with bypassing agents (aPCC and rFVIIa). In the study, patients received weekly Hemlibra prophylaxis (Arms A, C, and D) — 3 mg/kg once weekly for four weeks followed by 1.5 mg/kg once weekly thereafter — or no prophylaxis (Arm B). Patients randomised to Arm B could switch to Hemlibra prophylaxis after completing at least 24 weeks without prophylaxis. Dose up-titration to 3 mg/kg once weekly was allowed after 24 weeks on Hemlibra prophylaxis for patients who experienced two or more qualified bleeds (i.e., spontaneous and verified clinically significant bleeds occurring at steady state). At the time of the primary analysis, two patients underwent up-titration of their maintenance dose to 3 mg/kg once weekly.

Fifty-three patients previously treated with episodic (“on-demand”) bypassing agents were randomised in a 2:1 ratio to receive Hemlibra prophylaxis (Arm A) or no prophylaxis (Arm B), with stratification by prior 24-week bleed rate (< 9 or ≥9).

Forty-nine patients previously treated with prophylactic bypassing agents were enrolled in Arm C to receive Hemlibra prophylaxis. Seven patients previously treated with episodic (“on-demand”) bypassing agents who had participated in the NIS prior to enrolment but were unable to enroll in HAVEN 1 prior to the closure of Arms A and B were enrolled in Arm D to receive Hemlibra prophylaxis.

The primary objective of the study was to evaluate, among patients previously treated with episodic (“on-demand”) bypassing agents, the treatment effect of weekly Hemlibra prophylaxis compared with no prophylaxis (Arm A vs. Arm B) on the number of bleeds requiring treatment with coagulation factors over time (minimum of 24 weeks or date of discontinuation) (see Table 6). Other secondary objectives of the randomised comparison of Arms A and B were the efficacy of weekly Hemlibra prophylaxis in reducing the number of all bleeds, spontaneous bleeds, joint bleeds and target joint bleeds (see Table 6), as well as assessing patients' health-related quality of life (HRQoL) and health status (see Tables 10 and 11). The mean exposure time (+SD) for all patients on study was 21.38 weeks (12.01). For each treatment arm, the mean exposure times (+SD) were 28.86 weeks (8.37) for Arm A, 8.79 (3.62) for Arm B, 21.56 (11.85) for Arm C and 7.08 (3.89) for Arm D. One patient in Arm A withdrew from study prior to initiation of Hemlibra.

The study also evaluated the efficacy of weekly Hemlibra prophylaxis compared with previous episodic (on-demand) and prophylactic bypassing agents (separate comparisons) in patients who had participated in the NIS prior to enrolment (Arms A and C, respectively) (see Table 7).

*Patients (aged ≥ 12 years old) with haemophilia A with or without FVIII inhibitors (Study BO39182 – HAVEN 4)*

Hemlibra was investigated in a single arm, multicentre, phase III

clinical study in 41 adult and adolescent males (aged  $\geq 12$  years and  $> 40$  kg) who have haemophilia A with FVIII inhibitors or severe haemophilia A without FVIII inhibitors who previously received either episodic (“on demand”) or prophylactic treatment with bypassing agents or FVIII. Patients received Hemlibra prophylaxis – 3 mg/kg once weekly for four weeks followed by 6 mg/kg every four weeks thereafter. The primary objective of the study was to evaluate the efficacy of Hemlibra prophylaxis given every four weeks in maintaining adequate bleed control, based on treated bleeds. Other objectives were to evaluate the clinical efficacy of Hemlibra prophylaxis on all bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds (see Table 8). Patient treatment preference was also assessed using a preference survey.

*Patients (all ages) with mild or moderate haemophilia A without FVIII inhibitors (Study BO41423 – HAVEN 6)* The HAVEN 6 study was a multicentre, open-label, single-arm phase III clinical study in 71 emicizumab-treated patients (all ages) with mild (n = 20 [28.2%]) or moderate (n = 51 [71.8%]) haemophilia A without FVIII inhibitors for whom prophylaxis was indicated, as assessed by the investigator. Most patients were male (69 patients [97.2%]), and 2 were female (2.8%). At study entry, 34 patients (47.9%) were on episodic and 37 patients (52.1%) were on prophylactic treatment with FVIII. Patients received subcutaneous Hemlibra 3 mg/kg once weekly for the first four weeks followed by patient preference for one of the following maintenance regimens, from week 5: 1.5 mg/kg once weekly (n = 24 [33.8%]), 3 mg/kg every two weeks (n = 39 [54.9%]) or 6 mg/kg every four weeks (n = 8 [11.3%]). Dose up-titration to 3 mg/kg weekly was allowed after 24 weeks for patients who experienced two or more qualified bleeds (i.e., spontaneous and clinically significant bleeds occurring at steady state). At the time of interim analysis, no patients underwent up-titration of their maintenance dose.

The primary efficacy objective of the study was to evaluate the efficacy of Hemlibra prophylaxis based on the number of bleeds requiring treatment with coagulation factors over time (i.e., bleed rate of treated bleeds, see Table 9). Other objectives were to evaluate the efficacy of Hemlibra prophylaxis based on the number of all bleeds, spontaneous bleeds, joint bleeds, and target joint bleeds over time, as well as assessing patient reported HRQoL using the Comprehensive Assessment Tool of Challenges in Haemophilia (CATCH) questionnaire over time.

### Efficacy results

#### *HAVEN 3*

The efficacy results of Hemlibra prophylaxis compared with no prophylaxis with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 4.

**Table 4 HAVEN 3 study: Annualised Bleed Rate for Hemlibra prophylaxis arm versus no prophylaxis arm in patients  $\geq 12$  years of age without FVIII inhibitors**

<b>Endpoint</b>	<b>Arm C: No prophylaxis (N = 18)</b>	<b>Arm A: Hemlibra 1.5 mg/kg weekly (N = 36)</b>	<b>Arm B: Hemlibra 3 mg/kg every 2 weeks (N = 35)</b>
<b>Treated bleeds</b>			
ABR (95% CI)	38.2 (22.9; 63.8)	1.5 (0.9; 2.5)	1.3 (0.8; 2.3)
% reduction (RR), p-value	NA	96% (0.04), < 0.0001	97% (0.03), < 0.0001
% patients with 0 bleeds (95% CI)	0.0 (0.0; 18.5)	55.6 (38.1; 72.1)	60.0 (42.1; 76.1)
Median ABR (IQR)	40.4 (25.3; 56.7)	0 (0; 2.5)	0 (0; 1.9)
<b>All bleeds</b>			
ABR (95% CI)	47.6 (28.5; 79.6)	2.5 (1.6; 3.9)	2.6 (1.6; 4.3)
% reduction (RR), p-value	NA	95% (0.05), <0.0001	94% (0.06), <0.0001
% patients with 0 bleeds (95% CI)	0 (0.0; 18.5)	50 (32.9; 67.1)	40 (23.9; 57.9)
<b>Treated spontaneous bleeds</b>			
ABR (95% CI)	15.6 (7.6; 31.9)	1.0 (0.5; 1.9)	0.3 (0.1; 0.8)
% reduction (RR), p-value	NA	94% (0.06), <0.0001	98% (0.02), <0.0001
% patients with 0 bleeds (95% CI)	22.2 (6.4; 47.6)	66.7 (49.0; 81.4)	88.6 (73.3; 96.8)
<b>Treated joint bleeds</b>			
ABR (95% CI)	26.5 (14.67; 47.79)	1.1 (0.59; 1.89)	0.9 (0.44; 1.67)
% reduction (RR), p-value	NA	96% (0.04), <0.0001	97% (0.03), <0.0001
% patients with 0 bleeds (95% CI)	0 (0; 18.5)	58.3 (40.8; 74.5)	74.3 (56.7; 87.5)
<b>Treated target joint bleeds</b>			
ABR (95% CI)	13.0 (5.2; 32.3)	0.6 (0.3; 1.4)	0.7 (0.3; 1.6)
% reduction (RR), p-value	NA	95% (0.05), <0.0001	95% (0.05), <0.0001
% patients with 0 bleeds (95% CI)	27.8 (9.7; 53.5)	69.4 (51.9; 83.7)	77.1 (59.9; 89.6)

Rate ratio, and confidence interval (CI) come from negative binomial regression (NBR) model and p-value from Stratified Wald test, comparing bleed rate between specified arms.

Arm C: includes no prophylaxis period only.

Bleed definitions adapted based on ISTH criteria.

Treated bleeds = bleeds treated with FVIII

All bleeds = bleeds treated and not treated with FVIII.

Includes data before up-titration only, for patients whose dose was up-titrated.

Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.

ABR= Annualised Bleed Rate; CI= confidence interval; RR= rate ratio; IQR= interquartile range, 25th percentile to 75th percentile, NA=Not Applicable

In the HAVEN 3 clinical study intra-patient analysis, Hemlibra prophylaxis resulted in a statistically significant ( $p < 0.0001$ ) reduction (68 %) in bleed rate for treated bleeds compared with previous FVIII prophylaxis collected in the NIS prior to enrollment (see Table 5).

**Table 5 HAVEN 3 study: Intra-patient comparison of Annualised Bleed Rate (treated bleeds) with Hemlibra prophylaxis versus previous FVIII prophylaxis**

<b>Endpoint</b>	<b>Arm D NIS: Previous FVIII prophylaxis (N = 48)</b>	<b>Arm D: Hemlibra 1.5 mg/kg weekly (N = 48)</b>
Median efficacy period (weeks)	30.1	33.7
<b>Treated bleeds</b>		
ABR (95% CI) a	4.8 (3.2; 7.1)	1.5 (1; 2.3)
% reduction (RR), p-value	68% (0.32), <0.0001	
% patients with zero bleeds (95% CI)	39.6 (25.8; 54.7)	54.2 (39.2; 68.6)
Median ABR (IQR)	1.8 (0; 7.6)	0 (0; 2.1)

Rate ratio and confidence interval (CI) comes from negative binomial regression (NBR) model and p-value from Stratified Wald test, comparing ABR between specified arms. Intra-patient comparator data from the NIS. Only patients who participated in the NIS and in study HAVEN 3 are included.

Includes data before up-titration only, for patients whose dose was up-titrated.

Treated bleeds = bleeds treated with FVIII. Bleed definitions adapted based on ISTH criteria. ABR= Annualised Bleed Rate; CI= confidence interval; RR= rate ratio; IQR=interquartile range, 25th percentile to 75th percentile

Although a higher adherence was observed with emicizumab prophylaxis than with prior FVIII prophylaxis, no difference in ABR in patients with  $\geq 80\%$  or  $< 80\%$  compliant

doses on FVIII prophylaxis according to standard label requirements could be identified (data to be interpreted with caution due to small sample sizes).

Due to the short half-life of FVIII, no carryover effect is assumed after its discontinuation.

Only the first five emicizumab doses had to be administered under supervision to ensure safety and injection technique proficiency. Similar to FVIII prophylaxis, self-administration at home was allowed for all subsequent emicizumab doses.

All patients were treated by haemophilia experts who confirmed that adequate FVIII prophylaxis was administered to patients included in the intra-patient comparison, supporting equivalent usual prophylaxis care across sites and patients.

### *HAVEN 1*

The efficacy results of Hemlibra prophylaxis compared with no prophylaxis with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 6.

**Table 6 HAVEN 1: Annualised Bleed Rate with Hemlibra prophylaxis arm versus no prophylaxis arm in patients  $\geq$  12 years of age with FVIII inhibitors**

<b>Endpoint</b>	<b>Arm B: no prophylaxis</b>	<b>Arm A: 1.5 mg/kg Hemlibra weekly</b>
	N=18	N=35
<b>Treated bleeds</b>		
ABR (95% CI)	23.3 (12.33; 43.89)	2.9 (1.69; 5.02)
% reduction (RR), p-value	87% (0.13), < 0.0001	
% patients with 0 bleeds (95% CI)	5.6 (0.1; 27.3)	62.9 (44.9; 78.5)
Median ABR (IQR)	18.8 (12.97;35.08)	0 (0; 3.73)
<b>All bleeds</b>		
ABR (95% CI)	28.3 (16.79; 47.76)	5.5 (3.58; 8.60)
% reduction (RR), p-value	80% (0.20), < 0.0001	
% patients with 0 bleeds (95% CI)	5.6 (0.1; 27.3)	37.1 (21.5; 55.1)
<b>Treated spontaneous bleeds</b>		
ABR (95% CI)	16.8 (9.94; 28.30)	1.3 (0.73; 2.19)
% reduction (RR), p-value	92% (0.08), < 0.0001	
% patients with 0 bleeds (95% CI)	11.1 (1.4; 34.7)	68.6 (50.7; 83.1)
<b>Treated joint bleeds</b>		
ABR (95% CI)	6.7 (1.99; 22.42)	0.8 (0.26; 2.20)
% reduction (RR), p-value	89% (0.11), 0.0050	
% patients with 0 bleeds (95% CI)	50.0 (26.0; 74.0)	85.7 (69.7; 95.2)
<b>Treated target joint bleeds</b>		
ABR (95% CI)	3.0 (0.96; 9.13)	0.1 (0.03; 0.58)

% reduction (RR), p-value	95% (0.05), 0.0002	
% patients with 0 bleeds (95% CI)	50.0 (26.0; 74.0)	94.3 (80.8; 99.3)

Rate ratio, and confidence interval (CI) come from negative binomial regression (NBR) model and p-value from Stratified Wald test, comparing bleed rate between specified arms.

Arm B: includes no prophylaxis period only.

Bleed definitions adapted based on ISTH criteria.

Treated bleeds = bleeds treated with bypassing agents.

All bleeds = bleeds treated and not treated with bypassing agents.

Includes data before up-titration only, for patients whose dose was up-titrated.

Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.

ABR= Annualised Bleed Rate; CI= confidence interval; RR= rate ratio; IQR= interquartile range, 25<sup>th</sup> percentile to 75<sup>th</sup>percentile.

In the HAVEN 1 intra-patient analysis, Hemlibra prophylaxis resulted in statistically significant (p = 0.0003) and clinically meaningful reduction (79 %) in bleed rate for treated bleeds compared with previous bypassing agent prophylaxis collected in the NIS prior to enrolment (see Table 7).

**Table 7 HAVEN 1: Intra-patient comparison of Annualised Bleed Rate (treated bleeds) with Hemlibra prophylaxis versus previous bypassing agent prophylaxis (NIS patients)**

<b>Endpoint</b>	<b>Arm C<sub>NIS</sub>: previous bypassing agent prophylaxis</b>	<b>Arm C: Hemlibra 1.5 mg/kg weekly</b>
	N=24	N=24
<b>Treated bleeds</b>		
ABR (95% CI)	15.7 (11.08; 22.29)	3.3 (1.33; 8.08)
% patients with 0 bleeds (95% CI)	12.5 (2.7; 32.4)	70.8 (48.9; 87.4)
Median ABR (IQR)	12.0 (5.73; 24.22)	0.0 (0.00; 2.23)
% reduction (RR), p-value	79% (0.21), 0.0003	

Rate ratio and confidence interval (CI) comes from negative binomial regression (NBR) model and p-value from Stratified Wald test, comparing ABR between specified arms. Intra-patient comparator data from the NIS.

Only patients who participated in the NIS and in study HAVEN 1 are included.

Includes data before up-titration only, for patients whose dose was up-titrated.

Treated bleeds = bleeds treated with bypassing agents.

Bleed definitions adapted based on ISTH criteria.

ABR= Annualised Bleed Rate; CI= confidence interval; RR= rate ratio; IQR=interquartile range, 25<sup>th</sup> percentile to 75<sup>th</sup>percentile

Although a higher adherence was observed with emicizumab prophylaxis than with prior bypassing agent (BPA) prophylaxis, no difference in ABR in patients with ≥ 80% or < 80% compliant doses on BPA prophylaxis according to standard label

requirements could be identified (data to be interpreted with caution due to small sample sizes).

Due to the short half-life of bypassing agents, no carryover effect is assumed after its discontinuation.

Only the first five emicizumab doses had to be administered under supervision to ensure safety and injection technique proficiency. Similar to BPA prophylaxis, self-administration at home was allowed for all subsequent emicizumab doses.

#### *HAVEN 4*

Primary analysis efficacy results of Hemlibra prophylaxis every four weeks with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 8. Forty one patients  $\geq 12$  years old were evaluated for efficacy with a median observation time of 25.6 weeks (range: 24.1-29.4).

**Table 8 HAVEN 4: Annualised Bleed Rate with Hemlibra prophylaxis in patients  $\geq 12$  years of age with or without FVIII inhibitors**

Endpoints	Hemlibra 6mg/kg Q4W		
	<sup>a</sup> ABR (95% CI)	<sup>b</sup> Median ABR (IQR)	% Zero Bleeds (95%CI)
N	41	41	41
Treated bleeds	2.4 (1.4; 4.3)	0.0 (0.0; 2.1)	56.1 (39.7; 71.5)
All bleeds	4.5 (3.1; 6.6)	2.1 (0.0; 5.9)	29.3 (16.1; 45.5)
Treated spontaneous Bleeds	0.6 (0.3;1.5)	0.0 (0.0; 0.0)	82.9 (67.9;92.8)
Treated joint bleeds	1.7 (0.8; 3.7)	0.0 (0.0; 1.9)	70.7 (54.5; 83.9)
Treated target joint Bleeds	1.0 (0.3; 3.3)	0.0 (0.0;0.0)	85.4 (70.8; 94.4)

<sup>a</sup> Calculated with negative binomial regression (NBR) model

<sup>b</sup> Calculated ABR

Bleed definitions adapted based on ISTH criteria

Treated bleeds: bleeds treated with FVIII or rFVIIa

All bleeds: bleeds treated and not treated with FVIII or rFVIIa

Patients exposed to emicizumab started with a loading dose of 3mg/kg/week for 4 weeks.

ABR=Annualised Bleed Rate, CI=confidence interval; IQR=interquartile range; 25<sup>th</sup> percentile to 75<sup>th</sup> percentile ; Q4W=once every four week prophylaxis

#### *HAVEN 6 (interim analysis)*

Fifty-one patients with moderate haemophilia A aged 2 to 56 years old were evaluated for efficacy with a median observation time of 30.4 weeks (range: 17.4 - 61.7). Interim efficacy results of Hemlibra prophylaxis in patients with moderate haemophilia A (see section 4.1) with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 9.

**Table 9 HAVEN 6: Annualised Bleed Rate with Hemlibra prophylaxis in patients with moderate haemophilia A without FVIII inhibitors**

Endpoints	<sup>c</sup> Hemlibra 1.5 mg/kg QW, 3 mg/kg Q2W or 6 mg/kg Q4W		
	<sup>a</sup> ABR (95% CI)	<sup>b</sup> Median ABR (IQR)	% Zero Bleeds (95%CI)
N	51	51	51
Treated Bleeds	0.9 [0.43; 1.89]	0.0 [0.00; 0.00]	78.4 [64.7; 88.7]
All Bleeds	2.6 [1.81; 3.81]	1.7 [0.00; 3.90]	43.1 [29.3; 57.8]
Treated Spontaneous Bleeds	0.1 [0.03; 0.30]	0.0 [0.00; 0.00]	94.1 [83.8; 98.8]
Treated Joint Bleeds	0.3 [0.10; 0.84]	0.0 [0.00; 0.00]	90.2 [78.6; 96.7]
Treated Target Joint Bleeds	0.1 [0.02; 0.26]	0.0 [0.00; 0.00]	96.1 [86.5; 99.5]

<sup>a</sup> Calculated with negative binomial regression (NBR) model

<sup>b</sup> Calculated ABR

Bleed definitions adapted based on ISTH criteria

Treated bleeds: bleeds treated with FVIII.

All bleeds: bleeds treated and not treated with FVIII.

Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.

ABR=Annualised Bleed Rate, CI=confidence interval; IQR=interquartile range; 25<sup>th</sup> percentile to 75<sup>th</sup> percentile; QW=once every week prophylaxis; Q2W=once every two weeks prophylaxis; Q4W=once every four weeks prophylaxis

<sup>c</sup> 1.5 mg/kg QW (n = 16); 3 mg/kg Q2W (n = 30); 6 mg/kg Q4W (n = 5)

### Health-related outcome measures

The HAVEN clinical studies evaluated HRQoL and health-status using clinical outcome assessment measures. HAVEN 1 and 2 used the Haemophilia-Specific Quality of Life (Haem-A-QoL) questionnaire for adults ( $\geq 18$  years) and its adolescent version (Haemo-QoL-SF, for 8 to  $<18$  years), respectively, for which the Physical Health Score (i.e. painful swellings, presence of joint pain, pain with movement, difficulty walking far and needing more time to get ready) and Total Score (summary of all scores) were protocol defined endpoints of interest. HAVEN 2 additionally used the Adapted InhibQoL with Aspects of Caregiver Burden questionnaire to obtain caregiver-report of HRQoL in paediatric patients  $< 12$  years. HAVEN 6 assessed HRQoL in adult and paediatric patients, as well as caregivers of paediatric patients, using the Comprehensive Assessment Tool of Challenges in Haemophilia (CATCH) questionnaire. The domains of risk perception and impact of haemophilia on daily activities, social activities, recreational activities, and work/school, as well as preoccupation and treatment burden were examined. To measure change in health status, the Index Utility Score (IUS) and the Visual Analog Scale (VAS) from the EuroQoL Five-Dimension Five-Levels Questionnaire (EQ-5D-5L) were examined.



### *HAVEN 1 health-related outcomes*

In this study baseline Total Scores (mean = 41.14 and 44.58, respectively) and Physical Health scale scores (mean = 52.41 and 57.19, respectively) were similar for Hemlibra prophylaxis and no prophylaxis. Table 10 provides a summary of the comparison between the Hemlibra prophylaxis arm (Arm A) and the no prophylaxis arm (Arm B) on the Haem-A-QoL Total Score and Physical Health scale after 24 weeks of treatment adjusting for baseline. Weekly Hemlibra prophylaxis showed a statistically significant and clinically meaningful improvement compared with no prophylaxis in the pre-specified endpoints of Haem-A-QoL Physical Health Scale score at the Week 25 assessment.

**Table 10 HAVEN 1: Change in Haem-A-QoL Physical Health and Total score with Hemlibra prophylaxis versus no prophylaxis in patients  $\geq$  18 years with FVIII inhibitors**

<b>Haem-A-QoL at week 25</b>	<b>Arm B: no prophylaxis (N=14)</b>	<b>Arm A: Hemlibra 1.5 mg/kg weekly (N=25)</b>
<b>Physical health score (range 0 to 100)</b>		
Adjusted mean	54.17	32.61
Difference in adjusted means (95% CI)	21.55 (7.89, 35.22)	
p-value	0.0029	
<b>Total score (range 0 to 100)</b>		
Adjusted mean	43.21	29.2
Difference in adjusted means (95% CI)	14.01 (5.56, 22.45)	
<p>Arm B: includes no prophylaxis period only.            Includes data before up-titration only, for patients whose dose was up-titrated.            Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.            Haem-A_QoL scales range from 0 to 100; lower scores are reflective of better HRQoL.            Clinically meaningful difference: Total score: 7 points; Physical Health: 10 points.            Analyses are based on data from individuals who provided responses at both baseline and Week 25 assessments.</p>		

### *HAVEN 1 health status outcomes*

Table 11 provides a summary of the comparison between the Hemlibra prophylaxis arm (Arm A) and the no prophylaxis arm (Arm B) on the EQ-5D-5L IUS and VAS after 24 weeks of treatment adjusting for baseline.

**Table 11 HAVEN 1: EQ-5D-5L scores in patients  $\geq$  12 years at week 25**

<b>EQ-5D-5L scores after 24 weeks</b>	<b>Arm B: no prophylaxis (N=16)</b>	<b>Arm A: Hemlibra 1.5 mg/kg weekly (N=29)</b>
<b>Visual Analogue Scale</b>		

Adjusted mean	74.36	84.08
Difference in adjusted means (95% CI)	-9.72 (-17.62, -1.82)	
<b>Index Utility Score</b>		
Adjusted mean	0.65	0.81
Difference in adjusted means (95% CI)	-0.16 (-0.25, -0.07)	
<p>Arm B: includes no prophylaxis period only.  Includes data before up-titration only, for patients whose dose was up-titrated.  Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.  Higher scores indicate better quality of life.  Clinically meaningful difference: VAS: 7 points, Index Utility Score: 0.07 points  Analyses are based on data from individuals who provided responses at both baseline and Week 25 assessments.</p>		

#### *HAVEN 6 health-related outcomes*

In HAVEN 6, HRQoL for patients of all ages with moderate haemophilia A was evaluated at week 25 based on the CATCH questionnaire. The CATCH questionnaire (version 1.0) is a validated instrument that assesses the effect of haemophilia and its treatment. Different versions of the questionnaire exist for adult patients, paediatric patients and caregivers of paediatric patients. Health-related quality of life on Hemlibra prophylaxis remained generally stable, with improvement in the treatment burden domain of CATCH consistently observed across respondent groups.

#### *Paediatric population*

*Paediatric patients (age < 12 years old, or 12 to 17 years old weighing < 40 kg) with haemophilia A with FVIII inhibitors (Study BH29992 – HAVEN 2)*

Hemlibra weekly prophylaxis was evaluated in a single-arm, multicentre, open-label clinical study in paediatric patients (age < 12 years old, or 12 to 17 years old weighing < 40 kg) with haemophilia A with FVIII inhibitors. Patients received Hemlibra prophylaxis at 3 mg/kg once weekly for the first 4 weeks followed by 1.5 mg/kg once weekly thereafter.

The study evaluated the pharmacokinetics (PK), safety, and efficacy including the efficacy of weekly Hemlibra prophylaxis compared with previous episodic and prophylactic bypassing agent treatment in patients who had participated in the NIS prior to enrolment (intra-patient comparison).

#### *Efficacy results*

*HAVEN 2 (interim analysis)*

At the time of the interim analysis, efficacy was evaluated in 59 patients who were < 12 years old and had been receiving weekly Hemlibra prophylaxis for at least 12 weeks, including four patients aged < 2 years old, 17 patients aged 2 to < 6 years, 38 patients aged 6 to < 12 years old. Annualised bleed rate and percent of patients with zero bleeds were calculated (see Table 12). The median observation time for these patients was 29.6 weeks (range: 18.4 to 63.0 weeks).

**Table 12 HAVEN 2: Overview of efficacy (interim analysis)**

<b>Endpoint</b>	<b><sup>a</sup>ABR (95% CI) <sup>b</sup>N = 59</b>	<b><sup>c</sup>Median ABR (IQR) <sup>b</sup>N = 59</b>	<b>% Zero Bleeds (95% CI) <sup>b</sup>N = 59</b>
Treated bleeds	0.3 (0.1; 0.5)	0 (0; 0)	86.4 (75; 94)
All bleeds	3.8 (2.2; 6.5)	0 (0; 3.4)	55.9 (42.4; 68.8)
Treated spontaneous bleeds	0 (0; 0.2)	0 (0; 0)	98.3 (90.9; 100)
Treated joint bleeds	0.2 (0.1; 0.4)	0 (0; 0)	89.8 (79.2; 96.2)
Treated target joint bleeds	0.1 (0; 0.7)	0 (0; 0)	96.6 (88.3; 99.6)

ABR = annualised bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile

<sup>a</sup> Calculated with negative binomial regression (NBR) model.

<sup>b</sup> Efficacy data from treated patients aged < 12 years who had been on study HAVEN 2 for at least 12 weeks (N = 59), as the study aimed to primarily investigate treatment effect based on age.

<sup>c</sup> Calculated ABR

Bleed definitions adapted based on ISTH criteria.

Treated bleeds: bleeds treated with bypassing agents.

All bleeds: bleeds treated and not treated with bypassing agents.

Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.

In the intra-patient analysis, Hemlibra weekly prophylaxis resulted in a clinically meaningful reduction (98 %) in treated bleed rate in 18 paediatric patients who had at least 12 weeks of Hemlibra prophylaxis compared to their bleed rate collected in the NIS prior to enrolment (Table 13).

**Table 13 HAVEN 2: Intra-patient comparison of Annualised Bleed Rate (treated bleeds) with Hemlibra prophylaxis versus previous bypassing agent prophylaxis**

<b>Endpoint</b>	<b>Previous bypassing agent treatment* (N = 18)</b>	<b>Hemlibra prophylaxis (N = 18)</b>
<b>Treated bleeds</b>		
ABR (95% CI)	19.8 (15.3; 25.7)	0.4 (0.15; 0.88)
% reduction (RR)	98% (0.02)	

% patients with zero bleeds (95% CI)	5.6 (0.1; 27.3)	77.8 (52.4; 93.6)
Median ABR (IQR)	16.2 (11.49; 25.78)	0 (0; 0)

\* Previous prophylactic treatment for 15 of the 18 patients; previous episodic (on-demand) treatment for 3 subject

Rate ratio and confidence interval (CI) comes from negative binomial regression (NBR) model and p-value from Stratified Wald test, comparing ABR between specified arms. Intra-patient comparator data from the NIS.

Only patients who participated in the NIS and in study HAVEN 2 are included.

Bleed definitions adapted based on ISTH criteria.

Treated bleeds: bleeds treated with bypassing agents.

Patients exposed to emicizumab started with a loading dose of 3 mg/kg/week for 4 weeks.

ABR= Annualised Bleed Rate; CI= confidence interval; RR= rate ratio; IQR=interquartile range, 25<sup>th</sup> percentile to 75<sup>th</sup>percentile

Although a higher adherence was observed with emicizumab prophylaxis than with prior bypassing agent (BPA) prophylaxis, no difference in ABR in patients with  $\geq 80\%$  or  $< 80\%$  compliant doses on BPA prophylaxis according to standard label requirements could be identified (data to be interpreted with caution due to small sample sizes).

Due to the short half-life of bypassing agents, no carryover effect is assumed after its discontinuation.

Only the first five emicizumab doses had to be administered under supervision to ensure safety and injection technique proficiency. Similar to BPA prophylaxis, self-administration at home was allowed for all subsequent emicizumab doses.

### Paediatric health-related outcomes results

#### *HAVEN 2 health-related outcomes*

In HAVEN 2, HRQoL for patients aged  $\geq 8$  to  $< 12$  years was evaluated at week 25 based on the Haemo-QoL-SF questionnaire for children (see Table 14). The Haemo-QoL-SF is a valid and reliable measure of HRQoL. HRQoL for patients aged  $< 12$  years was also evaluated at week 25 based on the Adapted InhibQoL with Aspects of Caregiver Burden questionnaire completed by caregivers (see Table 14). The Adapted InhibQoL is a valid and reliable measure of HRQoL.

**Table 14 HAVEN 2: Change from baseline to week 25 in the Physical Health score of patients ( $< 12$  years of age) following treatment with Hemlibra prophylaxis as reported by patients and caregivers**

	Haemo-QoL-SF
<b>Physical health score (range 0 to 100)<sup>a</sup></b>	
Mean baseline score (95% CI) (n = 18)	29.5 (16.4 – 42.7)
Mean change from baseline (95% CI) (n = 15)	-21.7 (-37.1 - -6.3)
	<b>Adapted InhibQoL with aspects of caregiver burden</b>

<b>Physical health score (range 0 to 100)<sup>a</sup></b>	
Mean baseline score (95% CI) (n = 54)	37.2 (31.5 – 42.8)
Mean change from baseline (95% CI) (n = 43)	-32.4 (-38.6 - -26.2)
<sup>a</sup> Lower scores (negative change scores) are reflective of better functioning. Analyses are based on data from individuals who provided responses at both baseline and Week 25 assessments.	

There is limited experience with bypassing agent or FVIII use during surgeries and procedures. Bypassing agent or FVIII use during surgeries and procedures was determined by the investigator.

In the event of breakthrough bleeding, patients receiving emicizumab prophylaxis should be managed with available therapies. For bypassing agent guidance refer to section 4.4.

### Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response in patients treated with emicizumab. A total of 739 patients were tested for anti-emicizumab antibodies in the pooled clinical studies. Thirty-six patients (4.9%) tested positive for anti-emicizumab antibodies. In 19 patients (2.6%), anti-emicizumab antibodies were neutralising *in vitro*. Of these 19 patients, the neutralising anti-emicizumab antibodies did not have a clinically meaningful impact on the pharmacokinetics or efficacy of Hemlibra in 15 patients, while decreased emicizumab plasma concentrations were observed in four patients (0.5%). One patient (0.1%) with neutralising anti-emicizumab antibodies and decreased emicizumab plasma concentrations experienced loss of efficacy after five weeks of treatment and discontinued Hemlibra. Overall, the safety profile of Hemlibra was similar between those patients with anti-emicizumab antibodies (including neutralising antibodies) and those without (see sections 4.4 and 4.8).

### Elderly population

Use of Hemlibra in patients aged 65 and over with haemophilia A is supported by studies HAVEN 1, HAVEN 3, HAVEN 4 and HAVEN 6. Based on limited data, there is no evidence to suggest a difference in efficacy or safety in patients aged 65 years or above.

## **5.2 Pharmacokinetic properties**

The pharmacokinetics of emicizumab was determined via non-compartmental analysis in healthy subjects and using a population pharmacokinetic analysis on a database composed of 389 patients with haemophilia A.

### Absorption

Following subcutaneous administration in haemophilia A patients, the absorption half-life was 1.6 days.

Following multiple subcutaneous administrations of 3 mg/kg once weekly for the first 4 weeks in haemophilia A patients, mean ( $\pm$ SD) trough plasma concentrations of emicizumab achieved 52.6 $\pm$ 13.6  $\mu$ g/mL at Week 5.

The predicted mean ( $\pm$ SD)  $C_{\text{trough}}$ , and  $C_{\text{max}}$  and ratios of  $C_{\text{max}}/C_{\text{trough}}$  at steady-state for the recommended maintenance doses of 1.5 mg/kg once weekly, 3 mg/kg every two weeks or 6 mg/kg every four weeks are shown in Table 15 .


**Table 15 Mean ( $\pm$  SD) steady-state emicizumab concentrations**

Parameters	Maintenance dose		
	1.5 mg/kg once weekly	3 mg/kg every two weeks	6 mg/kg every four weeks
$C_{\text{max, ss}}$ ( $\mu$ g/mL)	54.9 $\pm$ 15.9	58.1 $\pm$ 16.5	66.8 $\pm$ 17.7
$C_{\text{avg, ss}}$ ( $\mu$ g/mL)	53.5 $\pm$ 15.7	53.5 $\pm$ 15.7	53.5 $\pm$ 15.7
$C_{\text{trough, ss}}$ ( $\mu$ g/mL)	51.1 $\pm$ 15.3	46.7 $\pm$ 16.9	38.3 $\pm$ 14.3
$C_{\text{max}}/C_{\text{trough}}$ ratio	1.08 $\pm$ 0.03	1.26 $\pm$ 0.12	1.85 $\pm$ 0.46

$C_{\text{avg, ss}}$  = average concentration at steady state;  $C_{\text{max, ss}}$  = maximum plasma concentration at steady state;  $C_{\text{trough, ss}}$  = trough concentration at steady state; QW = once weekly; Q2W = every two weeks; Q4W = every four weeks. Pharmacokinetic parameters derived from the population PK model.

Similar PK profiles were observed following once weekly dosing (3 mg/kg/week for 4 weeks followed by 1.5 mg/kg/week) in adults/adolescents ( $\geq$  12 years) and children (< 12 years) (see Figure 1).

**Figure 1: Mean ( $\pm$ 95% CI) plasma emicizumab concentration versus time profiles for patients  $\geq$  12 years (studies HAVEN 1 and HAVEN 3) compared with patients < 12 years (study HAVEN 2)**



In healthy subjects, the absolute bioavailability following subcutaneous administration of 1 mg/kg was between 80.4% and 93.1% depending on the injection site. Similar pharmacokinetic profiles were observed following subcutaneous administration in the abdomen, upper arm, and thigh. Emicizumab can be administered interchangeably at these anatomical sites (see section 4.2).

### Distribution

Following a single intravenous dose of 0.25 mg/kg emicizumab in healthy subjects, the volume of distribution at steady state was 106 mL/kg (i.e. 7.4 L for a 70-kg adult).

The apparent volume of distribution (V/F), estimated from the population PK analysis, in haemophilia A patients following multiple subcutaneous doses of emicizumab was 10.4 L.

### Metabolism

The metabolism of emicizumab has not been studied. IgG antibodies are mainly catabolised by lysosomal proteolysis and then eliminated from or reused by the body.

### Elimination

Following intravenous administration of 0.25 mg/kg in healthy subjects, the total clearance of emicizumab was 3.26 mL/kg/day (i.e. 0.228 L/d for a 70-kg adult) and the mean terminal half-life was 26.7 days.

Following a single subcutaneous injection in healthy subjects, the elimination half-life was approximately 4 to 5 weeks.

Following multiple subcutaneous injections in haemophilia A patients, the apparent clearance was 0.272 L/day and the elimination apparent half-life was 26.8 days.

### Dose linearity

Emicizumab exhibited dose-proportional pharmacokinetics in patients with haemophilia A after the first dose of Hemlibra over a dose range from 0.3 to 6 mg/kg . The exposure ( $C_{avg, ss}$ ) of multiple doses is comparable between 1.5 mg/kg every week, 3mg/kg every 2 weeks and 6mg/kg dose every 4 weeks.

### Special populations

#### Paediatric

The effect of age on the pharmacokinetics of emicizumab was assessed in a population pharmacokinetic analysis which included 5 infants ( $\geq 1$  month to  $< 2$  years), 55 children (less than 12 years) and 50 adolescents (12 to  $< 18$  years) with haemophilia A. Age did not affect the pharmacokinetics of emicizumab in paediatric patients.

#### Elderly

The effect of age on the pharmacokinetics of emicizumab was assessed in a population pharmacokinetic analysis which included thirteen subjects aged 65 years and older (no subjects were older than 77 years of age). Relative bioavailability decreased with older age, but no clinically important differences were observed in the pharmacokinetics of emicizumab between subjects  $< 65$  years and subjects  $\geq 65$  years.

#### Race

Population pharmacokinetics analyses in patients with haemophilia A showed that race did not affect the pharmacokinetics of emicizumab. No dose adjustment is required for this demographic factor.

#### Gender

Data in female patients are too limited for conclusion.

#### Renal impairment

No dedicated studies of the effect of renal impairment on the pharmacokinetics of emicizumab have been conducted.

Most of the patients with haemophilia A in the population pharmacokinetic analysis had normal renal function ( $N = 332$ ; creatinine clearance [CLcr]  $\geq 90$  mL/min) or mild renal impairment ( $N = 27$ ; CLcr of 60-89 mL/min). Mild renal impairment did not affect the pharmacokinetics of emicizumab. There are limited data available on the use of Hemlibra in patients with moderate renal impairment (only 2 patients with CLcr of 30-59 mL/min) and no data in patients with severe renal impairment. The impact of moderate and severe renal impairment on the pharmacokinetics of emicizumab cannot be concluded.

Emicizumab is a monoclonal antibody and is cleared via catabolism rather than renal excretion and a change in dose is not expected to be required for patients with renal impairment.



### Hepatic impairment

No dedicated studies on the effect of hepatic impairment on the pharmacokinetics of emicizumab have been conducted. Most of the patients with haemophilia A in the population pharmacokinetic analysis had normal hepatic function (bilirubin and AST  $\leq$  ULN, N = 300) or mild hepatic impairment (bilirubin  $\leq$  ULN and AST  $>$  ULN or bilirubin from 1.0 to 1.5  $\times$  ULN and any AST, N = 51). Only 6 patients had moderate hepatic impairment (1.5  $\times$  ULN  $<$  bilirubin  $\leq$  3  $\times$  ULN and any AST). Mild hepatic impairment did not affect the pharmacokinetics of emicizumab (see section 4.2). The safety and efficacy of emicizumab have not been specifically tested in patients with hepatic impairment. Patients with mild and moderate hepatic impairment were included in clinical studies. No data are available on the use of Hemlibra in patients with severe hepatic impairment.

Emicizumab is a monoclonal antibody and cleared via catabolism rather than hepatic metabolism and a change in dose is not expected to be required for patients with hepatic impairment.

### Other special populations

Modelling shows that less frequent dosing in patients with hypoalbuminemia and low body weight for their age results in lower emicizumab exposures; simulations indicate that these patients would still benefit from clinically meaningful bleed control. No patients with such characteristics were enrolled in clinical studies.

## **5.3 Preclinical safety data**

Preclinical data reveal no special hazards for humans based on studies of acute and repeated dose toxicity, including safety pharmacology endpoints and endpoints for reproductive toxicity.

### Fertility

Emicizumab did not cause any changes in the reproductive organs of male or female cynomolgus monkeys up to the highest tested dose of 30 mg/kg/week (equivalent to 11 times the human exposure at the highest dose of 3 mg/kg/week, based on AUC).

### Teratogenicity

No data are available with respect to potential side effects of emicizumab on embryo-foetal development. Injection site reactions

Reversible haemorrhage, perivascular mononuclear cell infiltration, degeneration/necrosis of subcutis, and swelling of endothelium in the subcutis was noted in animals after subcutaneous injection.

## **6. Pharmaceutical particulars**

### **6.1 List of excipients**

L-Arginine  
L-Histidine  
L-Aspartic acid  
Poloxamer 188  
Water for injections

### **6.2 Incompatibilities**

No incompatibilities between Hemlibra and polypropylene or polycarbonate syringes and stainless steel needles have been observed.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

### **6.3 Shelf life**

#### Unopened vial

24 months

Once removed from the refrigerator, unopened vials can be kept at room temperature (below 30°C) for up to 7 days.

After storage at room temperature, unopened vials may be returned to the refrigerator. If stored out of and then returned to refrigeration, the total combined time out of refrigeration should not exceed 7 days.

The vials should never be exposed to temperatures above 30 °C. Vials that have been kept at room temperature for more than 7 days or exposed to temperatures above 30 °C should be discarded.

#### Pierced vial and filled syringe

From a microbiological point of view, once transferred from the vial to the syringe, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

### **6.4 Special precautions for storage**

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Do not shake

Keep the vial in the outer carton in order to protect from light.

For storage conditions after first opening of the medicinal product, see

section 6.3.

## **6.5 Nature and contents of container**

### Hemlibra 30 mg/mL solution for injection

3 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film and crimped with an aluminium cap fitted with a plastic flip-off disk. Each vial contains 30 mg emicizumab in 1 mL of solution for injection. Each carton contains one vial.

### Hemlibra 150 mg/mL solution for injection

3 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film and crimped with an aluminium cap fitted with a plastic flip-off disk. Each vial contains 60 mg emicizumab in 0.4 mL of solution for injection. Each carton contains one vial.

3 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film and crimped with an aluminium cap fitted with a plastic flip-off disk. Each vial contains 105 mg emicizumab in 0.7 mL of solution for injection. Each carton contains one vial.

3 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film and crimped with an aluminium cap fitted with a plastic flip-off disk. Each vial contains 150 mg emicizumab in 1 mL of solution for injection. Each carton contains one vial.

Not all pack sizes may be marketed.

## **6.6 Special precautions for disposal and other handling**

Hemlibra solution is a sterile, preservative-free, and ready to use solution for subcutaneous injection that does not need to be diluted.

Hemlibra should be inspected visually to ensure there is no particulate matter or discolouration prior to administration. Hemlibra is a colourless to slightly yellow solution. Hemlibra solution should be discarded if particulate matter is visible or product is discoloured.

Hemlibra solution for injection vials are for single-use only.

A syringe, a transfer needle and an injection needle are needed to withdraw Hemlibra solution from the vial and inject it subcutaneously.

A 1 mL syringe should be used for an injection up to 1 mL of Hemlibra solution, whereas a 2 to 3 mL syringe should be used for an injection greater than 1 mL and up to 2 mL.

Selection criteria for syringes and needles are defined to ensure correct and safe administration of Hemlibra. These criteria are based on handling considerations (e.g. dosing accuracy, subcutaneous injection),

Hemlibra characteristics (e.g. viscosity), and compatibility between Hemlibra and device materials.

#### 1 mL syringe

Criteria: Transparent polypropylene or polycarbonate syringe with Luer-Lok™ tip, graduation 0.01 mL, sterile, for injection only, single-use, latex-free and non-pyrogenic, CE-marked.

#### 2 to 3 mL syringe

Criteria: Transparent polypropylene or polycarbonate syringe with Luer-Lok™ tip, graduation 0.1 mL, sterile, for injection only, single-use, latex-free and non-pyrogenic, CE-marked.

#### Transfer needle

Criteria: Stainless steel with Luer-Lok™ connection, sterile, gauge 18 G, length 35mm (1 1/2"), semi-blunted tip, single-use, latex-free and non-pyrogenic, CE-marked.

#### Injection needle

Criteria: Stainless steel with Luer-Lok™ connection, sterile, gauge 26 G, length preferably 9 mm (3/8") or maximally 13mm (1/2"), single-use, latex-free and non-pyrogenic, including needle safety feature, CE-marked.

### **Please see section 4.2 and package leaflet (section 7 Instructions for Use), for additional information on administration.**

The following procedures should be strictly adhered to regarding the use and disposal of syringes and needles:

- Needles and syringes should never be reused.
- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

### **7. Marketing authorization holder and manufacturing site**

#### **Marketing authorization holder:**

F. Hoffmann-La Roche Ltd.

Address: Grenzacherstrasse 124, CH-4070, Basel, Switzerland

#### **Manufacturing site address:**

#### **Manufacture of Drug Product (including filling/primary packaging)**

Chugai Pharma Manufacturing Co., Ltd. (CPMC)

Address: 16-3, Kiyohara Kogyodanchi Utsunomiya City, Tochigi,

#### **Labeling and Secondary Packaging**

F. Hoffmann-La Roche Ltd.

Address: Wurmisweg 4303 Kaiseraugst

### **8. Marketing authorisation number(s)**

CTD10354

**9. Date of first registration**

28/03/2023

**10. Date of revision of the text**

13/09/2023

**11. Dosimetry**

Not Applicable

**12. Instructions for Preparation of Radiopharmaceuticals**

Not Applicable

